ATE469969T1 - Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon - Google Patents

Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon

Info

Publication number
ATE469969T1
ATE469969T1 AT03795363T AT03795363T ATE469969T1 AT E469969 T1 ATE469969 T1 AT E469969T1 AT 03795363 T AT03795363 T AT 03795363T AT 03795363 T AT03795363 T AT 03795363T AT E469969 T1 ATE469969 T1 AT E469969T1
Authority
AT
Austria
Prior art keywords
human
mcp
antibodies
fragment
antibody
Prior art date
Application number
AT03795363T
Other languages
English (en)
Inventor
Kazuhisa Sugimura
Toshihiro Nakashima
Tsukasa Nishihara
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE469969T1 publication Critical patent/ATE469969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03795363T 2002-09-12 2003-09-10 Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon ATE469969T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002267184 2002-09-12
PCT/JP2003/011560 WO2004024921A1 (ja) 2002-09-12 2003-09-10 ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント

Publications (1)

Publication Number Publication Date
ATE469969T1 true ATE469969T1 (de) 2010-06-15

Family

ID=31986692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03795363T ATE469969T1 (de) 2002-09-12 2003-09-10 Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon

Country Status (11)

Country Link
US (1) US7342106B2 (de)
EP (1) EP1538207B1 (de)
JP (1) JP4426449B2 (de)
KR (1) KR20050042801A (de)
CN (1) CN1681926A (de)
AT (1) ATE469969T1 (de)
AU (1) AU2003262051B2 (de)
CA (1) CA2497804A1 (de)
DE (1) DE60332847D1 (de)
DK (1) DK1538207T3 (de)
WO (1) WO2004024921A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2097451A2 (de) 2006-12-22 2009-09-09 Ablynx N.V. Antichemokin-(ccl2, ccl3, ccl5, cxcl11, cxcl12) einzeldomänenantikörper
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2010001307A (es) * 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ｃｃｒ２에 대한 항체
DK2328930T3 (da) 2008-08-20 2015-03-30 Probiodrug Ag Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE)
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
BR112017002980A2 (pt) * 2014-08-15 2017-12-12 Pixarbio Corp composição para inibir a inflamação em um indivíduo com um dano na coluna vertebral, método para tratar inflamação em um indivíduo tendo um dano na coluna vertebral e kit para produzir a composição
EP3474859B1 (de) 2016-06-22 2025-12-24 Harless, William Warren Behandlung von krebs mit einem anti-krebs-stammzellenmittel in kombination mit einem neulsialidase-hemmer nach primärer krebstherapie
EP3551034A1 (de) 2016-12-07 2019-10-16 Progenity, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN112778414B (zh) * 2020-12-31 2022-04-15 中南大学湘雅二医院 cBIN1抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967399A (ja) 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
JP4298051B2 (ja) * 1999-04-13 2009-07-15 和久 杉村 抗ｍｃｐ−１抗体認識ペプチドミミックス、その製造方法およびその用途
AU2001258836A1 (en) * 2000-05-26 2001-12-03 Kensuke Egashira Preventives and remedies for pulmonary hypertension
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2003262051A1 (en) 2004-04-30
CN1681926A (zh) 2005-10-12
KR20050042801A (ko) 2005-05-10
US20060246069A1 (en) 2006-11-02
US7342106B2 (en) 2008-03-11
JPWO2004024921A1 (ja) 2006-01-12
EP1538207B1 (de) 2010-06-02
CA2497804A1 (en) 2004-03-25
JP4426449B2 (ja) 2010-03-03
DE60332847D1 (de) 2010-07-15
EP1538207A4 (de) 2006-05-24
WO2004024921A1 (ja) 2004-03-25
DK1538207T3 (da) 2010-07-05
EP1538207A1 (de) 2005-06-08
AU2003262051B2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
DE60332847D1 (de) Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
PE20020319A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
EP1885399A4 (de) Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
PE20110797A1 (es) Anticuerpos anti mn
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
NZ595450A (en) Antibodies to M-CSF
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
HRP20050986A2 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
NZ607711A (en) Antibodies directed to her-3 and uses thereof
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
NO20026063D0 (no) Antistoffer mot human MCP-1
PT1308507E (pt) Anticorpo monoclonal anti-núcleo de hcv
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
DE60136527D1 (de) Antikörper gegen eotaxin und deren verwendung
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
DE60238556D1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1538207

Country of ref document: EP